Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)Naveen Vasudev, Thomas Powles, Tom Waddell et al.|Journal of Clinical Oncology|2023Cited by 14
LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)Naveen Vasudev, T.B. Powles, Gemma Ainsworth et al.|Annals of Oncology|2021Cited by 9